BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Portfolio Pulse from
BrainStorm Cell Therapeutics has signed a Memorandum of Understanding with Pluri Inc. to manufacture NurOwn for a Phase 3b trial in ALS. This partnership will allow BrainStorm to transfer its manufacturing technology to Pluri's facility.
November 11, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BrainStorm Cell Therapeutics has partnered with Pluri Inc. to manufacture NurOwn for a Phase 3b ALS trial, potentially accelerating its development timeline.
The partnership with Pluri Inc. is crucial for BrainStorm as it allows the company to advance its Phase 3b trial for NurOwn, a key product in its pipeline. This could lead to faster development and potential market entry, positively impacting BCLI's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Pluri Inc. has signed an MOU with BrainStorm Cell Therapeutics to manufacture NurOwn for a Phase 3b ALS trial, enhancing its role in cell-based therapeutics manufacturing.
The agreement with BrainStorm enhances Pluri's position in the cell-based therapeutics manufacturing sector, potentially leading to increased business opportunities and revenue, which could positively impact PLUR's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80